title: Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer.
abstract: Breast cancer is one of the most common malignancies, often with complicated etiology and poor clinical outcome. In recent years, a critical role has emerged for the WW domain-containing oxidoreductase (WWOX) in breast cancer. WWOX is a tumor suppressor; it is deleted or attenuated in 29-63.2% of breast cancer tissues and is associated with a poor prognosis of breast cancer patients. WWOX heterozygous knockout mice show a higher incidence of mammary tumors and impaired branching morphogenesis. At the molecular level, WWOX interacts with AP2γ, ErbB4, SMAD3, and WBP2 suppressing their transcription activities in breast cancer cell lines. This review provides comprehensive insights into the current knowledge of WWOX activities in the pathogenesis and endocrine therapy of breast cancer.
authors.affiliation: Center for Translational Medicine, The First Affiliated Hospital, Xian Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, PR China.
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.affiliation: Center for Translational Medicine, The First Affiliated Hospital, Xian Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, PR China.
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Surgical Oncology, The First Affiliated Hospital, Xian Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, PR China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Ren
authors.affiliation: Center for Translational Medicine, The First Affiliated Hospital, Xian Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, PR China liupeijun@mail.xjtu.edu.cn.
authors.forename: Peijun
authors.initials: P
authors.lastname: Liu
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000502:physiology; D001943:Breast Neoplasms / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D063646:Carcinogenesis; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D006801:Humans; D051379:Mice; D010088:Oxidoreductases / Q000502:physiology*; D011379:Prognosis; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use; D025521:Tumor Suppressor Proteins / Q000502:physiology*; D000074584:WW Domain-Containing Oxidoreductase
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D020845:Selective Estrogen Receptor Modulators; D025521:Tumor Suppressor Proteins; D013629:Tamoxifen; D010088:Oxidoreductases; D000074584:WW Domain-Containing Oxidoreductase; C486071:WWOX protein, human
keywords: WW domain-containing oxidoreductase; breast cancer; endocrine therapy; tumorigenesis